1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Global Clinical Trials Review, H2, 2015

Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Global Clinical Trials Review, H2, 2015" provides an overview of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) to Respiratory Clinical Trials 14
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) to Respiratory Clinical Trials 18
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profile Snapshots 33
Appendix 65
Abbreviations 65
Definitions 65
Research Methodology 66
Secondary Research 66
About GlobalData 67
Contact Us 67
Disclaimer 67
Source 68

List of Tables
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials by Region, 2015* 6
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Proportion of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) to Respiratory Clinical Trials, G7 Countries (%), 2015* 15
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) to Respiratory Clinical Trials, E7 Countries (%), 2015* 19
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials by Phase, 2015* 22
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 27
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

List of Figures
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) to Respiratory Clinical Trials, G7 Countries (%), 2015* 14
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) to Respiratory Clinical Trials, E7 Countries (%), 2015* 18
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 27
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 66

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...

Global Clinical Trial Management System Growth, Trends and Forecasts (2017 - 2022)

Global Clinical Trial Management System Growth, Trends and Forecasts (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Global market for Clinical Trial Management System is expected to reach $2 billion by the end of 2020 growing at a CAGR of around 12.5% from 2014 to 2021. Clinical Trial Management System is a system ...

Global Clinical Trials Market Growth, Trends and Forecasts (2017 - 2022)

Global Clinical Trials Market Growth, Trends and Forecasts (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The global clinical trials market has been estimated to reach USD 14.2 billion in 2016 and is projected to reach around USD 22 billion by the year 2021, growing at a CAGR (compounded annual growth rate) ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.